摘要
目的探讨布地奈德对支气管哮喘患儿血清白细胞介素-4(IL-4),趋化素样因子-1(CKLF-1)和γ-干扰素(IFN-γ)水平的影响。方法选择2015年10月~2016年1月在我院就诊的84例支气管哮喘患儿,根据随机原则分为两组,其中采用布地奈德0.5 mg/次剂量雾化患儿为低剂量组,而采用布地奈德1.0 mg/次剂量雾化的患者为高剂量组,并取同时期40例同龄健康儿童作为对照组,比较两组患儿治疗后的临床症状评分变化情况,同时统计各组患者治疗前后的血清IL-4、CKLF-1和IFN-γ水平。结果两组患儿治疗后临床症状评分均有所下降,其中高剂量组患儿的下降程度明显优于低剂量组(P<0.05);两组患儿炎症因子水平治疗后均明显改善(P<0.05),高剂量组患儿三项炎症因子治疗后水平更接近于正常水平。结论布地奈德作为控制支气管哮喘患儿常用药物,雾化吸入能够有效控制临床症状,改善炎症因子水平,同时采用1.0 mg/次的剂量相较于0.5 mg/次的低剂量改善效果更明显,可供临床参考。
Objective To investigate the effects of budesonide on the levels of interleukin-4（IL-4）, chemokine-like factor-l（CKLF-1） and interferon-γ（IFN-γ） in children with bronchial asthma. Methods A total of 84 children patients with bronchial asthma who were enrolled in our hospital from October 2015 to January 2016 were selected. According to the principle of randomization, the patients were divided into two groups. Among them, the children who were given nebulized administration of 0.5 mg budesonide each time were assigned to the low dose group, and the children who were given nebulized administration of 1.0 mg budesonide each time were assigned to the high dose group. 40 healthy children with the same age were taken as the control group at the same period. The changes of clinical symptom scores were compared between the two groups after the treatment, and the levels of serum IL-4, CKLF-1 and IFN-γ were sta- tistically analyzed before and after the treatment in each groups. Results The clinical symptom scores were decreased after the treatment in both groups, and the decrease in the high dose group was significantly better than that in the low dose group. The difference was statistically significant （P〈0.05）; the levels of inflammatory factors had a significant im- provement after treatment（P〈0.05）. The three inflammatory factors were closer to the normal level after the treatment in the children patients in the high dose group. Conclusion Budesonide is a commonly used drug for controlling bronchial asthma in children. Aerosol inhalation can effectively control clinical symptoms, and improve the level of inflammatory factors, while the use of the dose of 1.0 mg each time compared to the low dose of 0.5 mg each time has a significant improvement effect, which can be provided to clinical reference.
出处
《中国现代医生》
2017年第3期4-6,共3页
China Modern Doctor
